Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with concurrent chemoradiotherapy and PD-1 maintenance for locally advanced cervical esophageal squamous cell carcinoma
ChiCTR2200066251Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Squamous Cell Carcinoma of the Cervical Esophagus, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: 2-year overall survival rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Squamous Cell Carcinoma of the Cervical Esophagus
Beyond the preview
Go deeper on ChiCTR2200066251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066251.